Patent application number | Description | Published |
20110083337 | APPARATUS FOR CHECKING THE ACCURACY OF A CIRCULAR PATH OF A MACHINE TOOL PERFORMED BY A WORK SPINDLE AND/OR A MACHINE TABLE - An apparatus for checking the accuracy of a circular path of a work spindle or a machine table, in particular an NC-controlled machine tool, includes a clamping element coaxial with the work spindle, a first rotary bearing disposed on the clamping element and coaxial with the rotation axis of the work spindle, a measurement arm with a first pivot bearing having a first pivot axis orthogonal to the rotation axis of the clamping element, a length measurement system disposed in measurement arm with a glass rod with a marking and a reading device, an adjusting device receiving the measurement arm and having a second pivot bearing with a pivot axis aligned parallel to the first pivot axis, a second rotary bearing having a second rotation axis aligned parallel to the rotation axis of the work spindle, and a stator supporting the second rotary bearing. | 04-14-2011 |
20120066922 | APPARATUS FOR TESTING THE ACCURACY OF MACHINE TOOLS AND MEASURING DEVICES - An apparatus for testing the accuracy of machine tools and measuring devices has a support and at least one reference element formed as a sleeve, wherein the reference element is glued on top of the support. | 03-22-2012 |
20130293375 | WIRELESS ALARM SYSTEM - A wireless alarm system has at least one radio controllable alarm unit for identifying and indicating a danger and at least one radio remote control device for releasing an alarm. The radio controllable alarm unit is arranged stationary in a freely selectable position inside a building and/or a community and/or a street and/or a landscape. | 11-07-2013 |
Patent application number | Description | Published |
20090238829 | Stabilized single domain antibodies - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 09-24-2009 |
20100113339 | Serum albumin binding proteins with long half-lives - The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. | 05-06-2010 |
20100226920 | MEDICAL DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE DOMAIN ANTIBODIES - The present invention relates to a pen-style administration device for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnoses. | 09-09-2010 |
20100330080 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 12-30-2010 |
20110021980 | NEEDLE-FREE DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE ANTIGEN-BINDING DOMAINS SUCH AS NANOBODIES.RTM. - The present invention relates to needle-free delivery devices for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnostic applications. | 01-27-2011 |
20110165621 | HUMANIZED ANTIBODIES - The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family Camelidae. | 07-07-2011 |
20110178277 | STABILIZED SINGLE DOMAIN ANTIBODIES - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 07-21-2011 |
20120251540 | STABILIZED SINGLE DOMAIN ANTIBODIES - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 10-04-2012 |
20140205606 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 07-24-2014 |
20150057436 | HUMANIZED ANTIBODIES - The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family Camelidae. | 02-26-2015 |
20150064182 | STABILIZED SINGLE DOMAIN ANTIBODIES - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 03-05-2015 |
20150218239 | FCRN Antagonists and Methods of Use - Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions. | 08-06-2015 |
20150239990 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 08-27-2015 |
20150246970 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 09-03-2015 |
20150252105 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 09-10-2015 |
Patent application number | Description | Published |
20120148607 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 06-14-2012 |
20120156206 | C-MET ANTIBODY COMBINATIONS - The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein. | 06-21-2012 |
20140141016 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 05-22-2014 |
20140147450 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 05-29-2014 |
20140235843 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 08-21-2014 |
20150140011 | IL-6 BINDING MOLECULES - The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer). | 05-21-2015 |
20150266963 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 09-24-2015 |